REspiratory syncytial virus

Sanofi SA (NASDAQ: SNY) and AstraZeneca plc (NASDAQ: AZN) have announced results from a prespecified pooled analysis of nirsevimab in respiratory syncytial virus (RSV). Results from the Phase 3 MELODY and Phase 2b nirsevimab trials demonstrated an efficacy (relative risk...

The FDA has granted Breakthrough Therapy Designation to Pfizer Inc's (NYSE: PFE) respiratory syncytial virus (RSV) vaccine candidate (PF-06928316 or RSVpreF) to prevent lower respiratory tract disease caused by RSV in 60 years of age or older. The positive results primarily...

Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), announced additional vaccine efficacy and safety data from its Phase 2b CYPRESS study of its respiratory syncytial virus (RSV) adult vaccine candidate.  J&J shared top-line findings from the Phase 2b...

Johnson & Johnson's (NYSE: JNJ) Janssen announced respiratory syncytial virus (RSV) vaccine candidate's efficacy as high as 80% in preventing severe infections in a mid-stage clinical trial. Related: Pfizer Starts Late-Stage Trial For RSV Vaccine Candidate...

Pfizer Inc (NYSE: PFE) has initiated a Phase 3 clinical trial evaluating its respiratory syncytial virus (RSV) bivalent prefusion F subunit investigational vaccine candidate (RSVpreF) in adults ages 60 years or older. The Phase 3 RENOIR trial will enroll approximately 30,000...

The thinly traded, small-cap biotech Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced results Friday from a midstage study. What Happened Enanta released top-line results from a Phase 2a study that evaluated EDP-938; it showed a highly statistically significant reduction in viral...

Two analysts reiterated their Neutral ratings on Novavax, Inc. (NASDAQ: NVAX) after the company announced what it said was positive data for its phase 2 safety and immunogenicity trial of its RSV F vaccine. Novavax was down 24.5 percent and trading at $1.14 at the time of writing, one day after...